1.1 Enrovit 10% Powder is an antibacterial drug containing 100 mg enrofloxacin hydrochloride in 1 g of the drug and such fillers as dextrose monohydrate or other sugar containing ingredients (lactose, sucrose).

1.2 The drug by its appearance is a homogeneous powder with yellow-white color

1.3 The drug is pre-packed into sealed double plastic bags or plastic jars by 100, 250, 500 and 1000 g.

1.4 The drug should be stored in dry, dark place, away from children within the temperature range +2°C to +30°C. Shelf life is 3 years from date of manufacture under specified storage conditions.

2.1 Enrofloxacin affects DNA gyrase, which inhibits apple acid biosynthesis in microorganisms. Enrofloxacin belonging to the fluoroquinolones group affects DNA gyrase, which inhibits apple acid biosynthesis in microorganisms, causing morphological changes in it and death. This particular mechanism of action eliminates possibility of the resistance growth with participation of plasmids which is caused by antibiotics and chemotherapeutic agents of previous generations.

2.2 Antibacterial effect of enrofloxacin has been detected against Gram-positive (Staphylococcus, Streptococcus, Corynebacterium, Clostridium and Listeria monocytogenes) and Gram-negative bacteria (E. coli, Salmonella, Klebsiella, Proteus, Yersinia, Haemophilus influenzae bacteria, Pasteurella, actinobacillus, Pseudomonas, Bordetella, Brucella, Campylobacter) and mycoplasmas.


3.1 The drug is prescribed for prevention and treatment of the following diseases in farm animals and poultry:

- in ruminants: enteritis, respiratory infections, colibacillosis, pasteurellosis, salmonellosis, mycoplasmosis, clostridioz, dysentery, leptospirosis;
- in poultry: chronic respiratory diseases, septicemia, chicken cholera and chicken typhoid, salmonella, staphilococcosis, streptococcosis, mycoplasmosis, vibriosis hepatitis, etc.;
- in rabbits: pasteurellosis, enterotoxemia, enteritis, dysentery, respiratory infections, listeriosis, endometritis, runny nose, rodentioz etc.;
- in pigs: bacterial diseases of gastrointestinal tract (colidiarrhea, colisepticemia) and bacterial;
- in fur-bearing animals (mink, fox Arctic fox), dogs: bacterial diseases of gastrointestinal tract and respiratory infections, leptospirosis.

3.2 The drug is administered orally or mixed with feed once a day with treatment purpose.
In ruminants, pigs and rabbits: a daily dose is based on 3-5g enrofloxacin per kg (0,3 – 0,5g of the drug per 10 kg) animal weight. Treatment course is 3-5 days, depending on the disease severity. In poultry - 100 g of the drug is diluted with 209 liters of drinking water and is administered within 3 days. In case of salmonellosis the treatment lasts up to 5 days.
In fur-bearing animals (mink, fox, Arctic fox) and dogs: a daily dose is based on 5g enrofloxacin per kg (0,5g of the drug per 10 kg) animal weight. Treatment course is 3-5 days, depending on the disease severity. Half dose is administered within 3-5 days for prevention treatment.

3.3 Veterinary Officer responsible for drug administration must monitor animals and birds.

3.4 Slaughter for meat of cattle, sheep, rabbits and chickens shall be allowed no earlier than 7 days, pigs - 5 days, turkeys - 14 days after the last drug administration. Milk and eggs shall not be used for food purposes within 7 days after the last drug administration. Meat of urgently slaughtered animals as well as milk shall be used for feeding purpose only.


4.1 A person working with this drug shall follow general personal hygiene regulations and safety precautions prescribed for operations with veterinary drugs.

4.2 After finishing work you should wash your hands with warm water and soap.  


5.1 In case of inconsistency of the drug with requirements of this Instruction, its use should be discontinued and reported to the Uzbek State Scientific and Veterinary Drugs Control Laboratory at: 700178, Tashkent, No.1a, A.Yunusov Street. Tel. / Fax: 228-76-14, 229-30 - 47. E-mail: uzgnkl@rambler.ru. Simultaneously unpacked drug package should be sent to the laboratory address with the drug in quantity previously agreed with laboratory including detailed description of the nature of complaints regarding its inconsistency with this Instruction.